CY1125052T1 - Κρυσταλλικες μορφες - Google Patents

Κρυσταλλικες μορφες

Info

Publication number
CY1125052T1
CY1125052T1 CY20221100195T CY221100195T CY1125052T1 CY 1125052 T1 CY1125052 T1 CY 1125052T1 CY 20221100195 T CY20221100195 T CY 20221100195T CY 221100195 T CY221100195 T CY 221100195T CY 1125052 T1 CY1125052 T1 CY 1125052T1
Authority
CY
Cyprus
Prior art keywords
crystal forms
pharmaceutical compositions
crystalline forms
crystalline
phosphono
Prior art date
Application number
CY20221100195T
Other languages
Greek (el)
English (en)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CY1125052T1 publication Critical patent/CY1125052T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20221100195T 2016-09-22 2022-03-09 Κρυσταλλικες μορφες CY1125052T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
CY1125052T1 true CY1125052T1 (el) 2024-02-16

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100195T CY1125052T1 (el) 2016-09-22 2022-03-09 Κρυσταλλικες μορφες

Country Status (27)

Country Link
US (4) US10730896B2 (https=)
EP (2) EP3981774A1 (https=)
JP (1) JP7097369B2 (https=)
KR (1) KR102552795B1 (https=)
CN (1) CN109715639B (https=)
AU (1) AU2017331930B2 (https=)
CA (1) CA3037794A1 (https=)
CL (1) CL2019000728A1 (https=)
CY (1) CY1125052T1 (https=)
DK (1) DK3515924T3 (https=)
EA (1) EA201990723A1 (https=)
ES (1) ES2908572T3 (https=)
HR (1) HRP20220234T1 (https=)
HU (1) HUE057772T2 (https=)
IL (1) IL265445B2 (https=)
LT (1) LT3515924T (https=)
MA (1) MA46266B1 (https=)
MX (1) MX381590B (https=)
MY (1) MY193080A (https=)
PH (1) PH12019500567B1 (https=)
PL (1) PL3515924T3 (https=)
PT (1) PT3515924T (https=)
RS (1) RS62946B1 (https=)
SI (1) SI3515924T1 (https=)
TW (1) TWI752086B (https=)
UA (1) UA124073C2 (https=)
WO (1) WO2018055016A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
PT4181872T (pt) 2020-07-15 2026-01-22 Viatris Asia Pacific Pte Ltd Composição farmacêutica aquosa compreendendo um antagonista do recetor p2y12
JP2024524658A (ja) * 2021-07-13 2024-07-05 イドルシア・ファーマシューティカルズ・リミテッド 4-((r)-2-{[6-((s)-3-メトキシ-ピロリジン-1-イル)-2-フェニル-ピリミジン-4-カルボニル]-アミノ}-3-ホスホノ-プロピオニル)-ピペラジン-1-カルボン酸ブチルエステルの合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
CA2521313A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
WO2007046075A1 (en) 2005-10-21 2007-04-26 Actelion Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
KR20100015886A (ko) 2007-04-23 2010-02-12 사노피-아벤티스 P2y12 길항제로서의 퀴놀린-카복스아미드 유도체
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
KR101694563B1 (ko) 2009-04-08 2017-01-09 액테리온 파마슈티칼 리미티드 Adp 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘
EP2421859B1 (en) 2009-04-22 2014-04-09 Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as p2y12 receptor antagonists
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
PT4181872T (pt) 2020-07-15 2026-01-22 Viatris Asia Pacific Pte Ltd Composição farmacêutica aquosa compreendendo um antagonista do recetor p2y12

Also Published As

Publication number Publication date
IL265445B1 (en) 2024-01-01
IL265445B2 (en) 2024-05-01
US12227532B2 (en) 2025-02-18
US11365209B2 (en) 2022-06-21
TWI752086B (zh) 2022-01-11
EP3981774A1 (en) 2022-04-13
EP3515924A1 (en) 2019-07-31
US10730896B2 (en) 2020-08-04
TW201813965A (zh) 2018-04-16
KR20190052704A (ko) 2019-05-16
MY193080A (en) 2022-09-26
HRP20220234T1 (hr) 2022-05-13
EA201990723A1 (ru) 2019-10-31
LT3515924T (lt) 2022-03-10
JP2019529553A (ja) 2019-10-17
NZ750772A (en) 2023-10-27
CN109715639A (zh) 2019-05-03
IL265445A (en) 2019-05-30
MX381590B (es) 2025-03-12
US20220275011A1 (en) 2022-09-01
PT3515924T (pt) 2022-03-11
KR102552795B1 (ko) 2023-07-06
MA46266A (fr) 2019-07-31
MA46266B1 (fr) 2022-02-28
UA124073C2 (uk) 2021-07-14
US20200017534A1 (en) 2020-01-16
PH12019500567A1 (en) 2019-11-18
CL2019000728A1 (es) 2019-07-05
AU2017331930A1 (en) 2019-03-07
ES2908572T3 (es) 2022-05-03
CA3037794A1 (en) 2018-03-29
US20210009614A1 (en) 2021-01-14
EP3515924B1 (en) 2021-12-15
HUE057772T2 (hu) 2022-06-28
US20250163086A1 (en) 2025-05-22
BR112019004845A2 (pt) 2019-06-04
PL3515924T3 (pl) 2022-04-11
JP7097369B2 (ja) 2022-07-07
PH12019500567B1 (en) 2024-01-31
CN109715639B (zh) 2022-04-19
RS62946B1 (sr) 2022-03-31
AU2017331930B2 (en) 2021-07-15
SI3515924T1 (sl) 2022-04-29
DK3515924T3 (da) 2022-03-21
WO2018055016A1 (en) 2018-03-29
MX2019003093A (es) 2019-07-18

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1125052T1 (el) Κρυσταλλικες μορφες
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
MX391812B (es) Agonista fxr derivado de esteroides.
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
JOP20220305A1 (ar) ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201790275A1 (ru) Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида